20/20 Biolabs, Inc. filed its quarterly report on Form 10-Q with the SEC on November 16, 2026, covering the three and nine months ended September 30, 2026, disclosing a net loss of $5,056,270 for the nine-month period and reporting significant changes to its capital structure.
Key Highlights
- Nine-month net loss: The company reported a net loss of $5,056,270 for the nine months ended September 30, 2026, compared to $2,431,050 for the same period in 2025, according to the filing.
- Revenue decline: Revenues for the nine months ended September 30, 2026 were $1,464,162, down from $1,506,859 in the comparable prior-year period, the filing disclosed.
- Cash position: Cash and cash equivalents stood at $3,633,711 as of September 30, 2026, up from $1,025,987 at December 31, 2025, per the balance sheet.
- Shares outstanding: As of November 13, 2026, there were 13,992,168 shares of common stock issued and outstanding, as stated in the filing.
- Series E preferred stock issued: 5,015 shares of Series E convertible preferred stock were issued and outstanding as of September 30, 2026, with a liquidation preference of $5,639,555, according to the balance sheet.
- Operating expenses rose: Total operating expenses for the nine months ended September 30, 2026 were $4,541,960, compared to $2,892,149 in the same period of 2025, the filing stated.
- Net loss attributable to common stockholders: After preferred stock dividends of $304,295 and a deemed dividend on warrant modifications of $1,124,676, net loss attributable to common stockholders for the nine months was $6,485,241, or $0.62 per basic and diluted share.
20/20 Biolabs Financial Results and Capital Activity for the Quarter Ended September 30, 2026
20/20 Biolabs, Inc. (NASDAQ:AIDX) reported revenues of $380,216 for the three months ended September 30, 2026, compared to $417,979 in the same quarter of 2025, according to the filing. Gross profit for the third quarter of 2026 was $96,873, down from $145,066 in the year-earlier quarter. For the nine-month period, the company reported revenues of $1,464,162 and a gross profit of $464,484.
Total operating expenses for the three months ended September 30, 2026 were $1,486,770, including sales, general and administrative expenses of $1,363,385 and research and development expenses of $123,385, the filing disclosed. This compares to total operating expenses of $945,239 for the third quarter of 2025. For the nine months ended September 30, 2026, interest expense was $539,253, the company also reported a loss on issuance of convertible notes of $326,595, and a loss on change in fair value of warrant liability of $148,766, contributing to total other expense of $978,794 for that period.
On the balance sheet, total assets were $5,018,102 as of September 30, 2026, compared to $4,137,357 at December 31, 2025. Total liabilities decreased to $2,850,599 from $4,156,582 over the same period, according to the filing. The accumulated deficit grew to $38,303,489 as of September 30, 2026, from $33,247,219 at December 31, 2025. Common shares issued and outstanding increased to 13,367,204 as of September 30, 2026, from 5,442,249 at December 31, 2025, reflecting conversions of multiple series of preferred stock into common stock during the period, as shown in the statements of stockholders' equity.
What Was Disclosed
20/20 Biolabs, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, reporting a nine-month net loss of $5,056,270, revenues of $1,464,162, cash of $3,633,711, and a substantial increase in common shares outstanding following preferred stock conversions.



Please wait processing your request...